CeQur

The CeQur management team has members with proven records of success in the fields of diabetes and medical device development. Together, the team has the competencies, experience and passion to successfully commercialize safe and effective advances in drug delivery technology.

Eric Milledge

Chairman & Chairman of the Board of CeQur. Milledge is a 34-year veteran of Johnson and Johnson Corporation, where he retired as Group Chairman of Lifescan. During his tenure, Milledge led the acquisition of Animas Corporation, which enabled J&J to become a major force in the insulin pump arena. Milledge had also served as president of Ortho Pharmaceuticals and as a board member of the Johnson and Johnson Development Corporation, the company's internal venture arm.

Robert Farra

Chief Executive Officer of CeQur. Farra has a more than 30-year record of leading organizations in the development of novel products, including drug delivery devices, combination products, medical devices, life support systems, and sensors in the diabetes, cardiac, and surgical fields. Prior to joining CeQur, he was with Microchips Biotech, a developer of wirelessly-enabled drug delivery and sensing implants, where he held senior roles including president, chief technology officer, chief operations officer, and vice president of R&D. Prior to Microchips, Farra was vice president of both engineering and manufacturing at Abiomed, developing the total implantable artificial heart, ventricular assist devices and intra-aortic balloon pumps. Farra earned his SMME degree from MIT and has over twenty patents.

Douglas Gunthardt

Executive Vice President and Chief Financial Officer of CeQur. Douglas has 20 years international leadership experience with both American high-tech and Swiss life science corporations in business development, finance and general management. He was former CEO CFO of Siegfried (SWX:SFZN) and Int'l Director F & A of Haemonetics. He currently serves as a board member of Ricola AG.

Robert O'Holla

Executive Vice President of Regulatory Affairs, CeQur. O'Holla began his regulatory career in 1975, after several years in medical device and drug development. He spent 33 years at Johnson & Johnson, where he most recently served as worldwide vice president of regulatory affairs in the medical devices and diagnostics group. O'Holla is a longtime leader in AdvaMed, the premier medical technology industry group, and has been recognized by both this organization and the Regulatory Affairs Professionals Society as an outstanding professional and contributor in his field.

Jay Warner

Senior Vice President Clinical and Commercialization at CeQur. Warner's career in diabetes marketing and sales spanned 16 years at Eli Lilly and Company, where he served as Leader for the U.S. Byetta brand team and led the U.S. and Global Diabetes Market Research. While at Lilly, Warner was instrumental in the successful launch of more than seven new diabetes products.